Role of matrix metalloproteinases in the development of airway inflammation and remodeling

Brazilian Journal of Medical and Biological Research

Volumn 38, Issue 10, 2005, Pages 1521-1530

  Lagente, Vincent ^a   Manoury, B ^a   Nenan S ^a   Le Quement C ^a   Martin Chouly, C ^a   Boichot, E ^a  

^a UNIVERSITÉ DE RENNES 1   (France)

Author keywords

Chronic obstructive pulmonary disease; Fibrosis; Inflammation; Lung; Matrix metalloproteinase; Tissue inhibitor of matrix metalloproteinases

Indexed keywords

BATIMASTAT; BLEOMYCIN; CILOMILAST; COLLAGEN; COLLAGENASE; COLLAGENASE 3; CORTICOSTEROID; DEXAMETHASONE; ELASTASE; ELASTIN; GELATINASE A; GELATINASE B; GLUCOCORTICOID; HYDROXYPROLINE; INTERSTITIAL COLLAGENASE; MACROPHAGE ELASTASE; MARIMASTAT; MATRILYSIN; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE 14; NEUTROPHIL COLLAGENASE; PHOSPHODIESTERASE IV INHIBITOR; ROLIPRAM; STROMELYSIN; STROMELYSIN 2; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TISSUE INHIBITOR OF METALLOPROTEINASE 3; TISSUE INHIBITOR OF METALLOPROTEINASE 4; UNINDEXED DRUG;

CHRONIC OBSTRUCTIVE LUNG DISEASE; DISEASE COURSE; DISEASE MODEL; DRUG ACTIVITY; DRUG EFFICACY; EMPHYSEMA; ENZYME ACTIVITY; EXTRACELLULAR MATRIX; HUMAN; LUNG DISEASE; LUNG FIBROSIS; LUNG INTERSTITIUM; LUNG LAVAGE; NONHUMAN; PATHOGENESIS; PROTEIN DEGRADATION; REGULATORY MECHANISM; RESPIRATORY TRACT INFLAMMATION; REVIEW; SYMPTOM; TISSUE REPAIR;

EID: 26644438095     PISSN: 0100879X     EISSN: 1414431X     Source Type: Journal    
DOI: 10.1590/S0100-879X2005001000009     Document Type: Review

References (59)

1. Birkedal-Hansen H (1995). Proteolytic remodeling of extracellular matrix. Current Opinion in Cell Biology, 7: 728-735.
2. Murphy G & Docherty A (1992). The matrix metalloproteinases and their inhibitors. American Journal of Respiratory Cell and Molecular Biology, 7: 120-125.
3. Pauwels R (2000). COPD: the scope of the problem in Europe. Chest, 117: 332S-335S.
4. Saetta M (1999). Airway inflammation in chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine, 160: S17-S20.
5. Eidelman D, Saetta MP, Ghezzo H et al. (1990). Cellularity of the alveolar walls in smokers and its relation to alveolar destruction. Functional implications. American Review of Respiratory Disease, 141: 1547-1552.
6. Finkelstein R, Fraser RS, Ghezzo H et al. (1995). Alveolar inflammation and its relation to emphysema in smokers. American Journal of Respiratory and Critical Care Medicine, 152: 1666-1672.
7. Tetley TD (2002). Macrophages and the pathogenesis of COPD. Chest, 121: 156S-159S.
8. Shapiro SD & Senior RM (1999). Matrix metalloproteinases. Matrix degradation and more. American Journal of Respiratory Cell and Molecular Biology, 20: 1100-1102.
9. Finlay GA, O'Driscoll LR, Russell KJ et al. (1997). Matrix metalloproteinase expression and production by alveolar macrophages in emphysema. American Journal of Respiratory and Critical Care Medicine, 156: 240-247.
10. Betsuyaku T, Shipley JM, Liu Z et al. (1999). Neutrophil emigration in the lungs, peritoneum, and skin does not require gelatinase B. American Journal of Respiratory Cell and Molecular Biology, 20: 1303-1309.
11. Ohnishi K, Takagi M, Kurokawa Y et al. (1998). Matrix metalloproteinase-mediated extracellular matrix protein degradation in human pulmonary emphysema. Laboratory Investigation, 78: 1077-1087.
12. Kang MJ, Oh YM, Lee JC et al. (2003). Lung matrix metalloproteinase-9 correlates with cigarette smoking and obstruction of airflow. Journal of Korean Medical Science, 18: 821-827.
13. Lim S, Roche N, Oliver BG et al. (2000). Balance of matrix metalloprotease-9 and tissue inhibitor of metalloproteinase-1 from alveolar macrophages in cigarette smokers. Regulation by interleukin-10. American Journal of Respiratory and Critical Care Medicine, 162: 1355-1360.
14. Russell RE, Culpitt SV, DeMatos C et al. (2002). Release and activity of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 by alveolar macrophages from patients with chronic obstructive pulmonary disease. American Journal of Respiratory Cell and Molecular Biology, 26: 602-609.
15. Russell RE, Thorley A, Culpitt SV et al. (2002). Alveolar macrophage-mediated elastolysis: roles of matrix metalloproteinases, cysteine, and serine proteases. American Journal of Physiology, 283: L867-L873.
16. Cataldo D, Munaut C, Noel A et al. (2000). MMP-2- and MMP-9-linked gelatinolytic activity in the sputum from patients with asthma and chronic obstructive pulmonary disease. International Archives of Allergy and Immunology, 123: 259-267.
17. Shapiro SD, Kobayashi DK & Ley TJ (1993). Cloning and characterization of a unique elastolytic metalloproteinase produced by human alveolar macrophages. Journal of Biological Chemistry, 268: 23824-23829.
18. Gronski TJ, Martin RL, Kobayashi DK et al. (1997). Hydrolysis of a broad spectrum of extracellular matrix proteins by human macrophage elastase. Journal of Biological Chemistry, 272: 12189-12194.
19. Starcher BC (1986). Elastin and the lung. Thorax, 41: 577-585.
20. Shapiro SD (2000). Evolving concepts in the pathogenesis of chronic obstructive pulmonary disease. Clinics in Chest Medicine, 21: 621-632.
21. Stone PJ, Gottlieb DJ, O'Connor GT et al. (1995). Elastin and collagen degradation products in urine of smokers with and without chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine, 151: 952-959.
22. Gottlieb DJ, Stone PJ, Sparrow D et al. (1996). Urinary desmosine excretion in smokers with and without rapid decline of lung function: the Normative Aging Study. American Journal of Respiratory and Critical Care Medicine, 154: 1290-1295.
23. Molet S, Belleguic C, Léna H et al. (2004). Increase in macrophage elastase (MMP-12) in lungs from patients with chronic obstructive pulmonary disease. Inflammation Research, 54: 31-36.
24. Hautamaki RD, Kobayashi DK, Senior RM et al. (1997). Requirement for macrophage elastase for cigarette smoke-induced emphysema in mice. Science, 277: 2002-2004.
25. Selman M, Cisneros-Lira J, Gaxiola M et al. (2003). Matrix metalloproteinases inhibition attenuates tobacco smoke-induced emphysema in guinea pigs. Chest, 123: 1633-1641.
26. Senior RM, Griffin GL & Mecham RP (1980). Chemotactic activity of elastin-derived peptides. Journal of Clinical Investigation, 66: 859-862.
27. Valença SS, Da Hora K, Castro P et al. (2004). Emphysema and metalloelastase expression in mouse lung induced by cigarette smoke. Toxicologic Pathology, 32: 351-356.
28. Churg A, Zay K, Shay S et al. (2002). Acute cigarette smoke-induced connective tissue breakdown requires both neutrophils and macrophage metalloelastase in mice. American Journal of Respiratory Cell and Molecular Biology, 27: 368-374.
29. Leclerc O, Planquois JM, Lagente V et al. (2004). A model of cigarette smoke-induced COPD inflammation in mice: steroid-in-sensitive but PDE4 sensitive. International Meeting on Nitric Oxide, Cytokines and Inflammation, Rio de Janeiro, RJ, Brasil, June 6-9 (Abstract).
30. Nenan S, Planquois JM, Berna P et al. (2005). Analysis of the inflammatory response induced by rhMMP-12 catalytic domain instilled in mouse airways. International Immunopharmacology, 5: 511-524.
31. Selman M, King TE & Pardo A (2001). Idiopathic pulmonary fibrosis: prevailing and evolving hypotheses about its pathogenesis and implications for therapy. Annals of Internal Medicine, 134: 136-151.
32. Katzenstein AL & Myers JL (1998). Idiopathic pulmonary fibrosis: clinical relevance of pathologic classification. American Journal of Respiratory and Critical Care Medicine, 157: 1301-1315.
33. Ward PA & Hunninghake GW (1998). Lung inflammation and fibrosis. American Journal of Respiratory and Critical Care Medicine, 157: S123-S129.
34. Kolb M, Bonniaud P, Galt T et al. (2002). Differences in the fibrogenic response after transfer of active transforming growth factor-beta1 gene to lungs of "fibrosis-prone" and "fibrosis-resistant" mouse strains. American Journal of Respiratory Cell and Molecular Biology, 27: 141-150.
35. Gauldie J, Kolb M & Sime PJ (2002). A new direction in the pathogenesis of idiopathic pulmonary fibrosis? Respiratory Research, 3: 1.
36. Santana A, Saxena B, Noble NA et al. (1995). Increased expression of transforming growth factor beta isoforms (beta 1, beta 2, beta 3) in bleomycin-induced pulmonary fibrosis. American Journal of Respiratory Cell and Molecular Biology, 13: 34-44.
37. Coker RK, Laurent GJ, Shahzeidi S et al. (1997). Transforming growth factors-beta 1, -beta 2, and -beta 3 stimulate fibroblast procollagen production in vitro but are differentially expressed during bleomycin-induced lung fibrosis. American Journal of Pathology, 150: 981-991.
38. O'Connor C, Odlum C, Van Breda A et al. (1998). Collagenase and fibronectin in bronchoalveolar lavage fluid in patients with sarcoidosis. Thorax, 43: 393-400.
39. Gadeck JE, Kelman JA, Fens GA et al. (1979). Collagenase in the lower respiratory tract of patients with idiopathic pulmonary fibrosis. New England Journal of Medicine, 301: 737-742.
40. Selman M & Pardo A (1991). Potential role of proteases in pulmonary fibrosis. Annals of the New York Academy of Sciences, 624: 297-306.
41. Fukuda Y, Ishizaki M, Kudoh S et al. (1998). Localisation of matrix metalloproteinases-1, -2, and -9 and tissue inhibitor of metalloproteinase-2 in interstitial lung diseases. Laboratory Investigation, 78: 687-698.
42. Hayashi T, Stetler-Stevenson WG, Fleming MY et al. (1996). Immunohistochemical study of metalloproteinases and their tissue inhibitors in the lungs of patients with diffuse alveolar damage and idiopathic pulmonary fibrosis. American Journal of Pathology, 149: 1241-1256.
43. Pardo A, Selman M, Ramirez R et al. (1992). Production of collagenase and tissue inhibitor of metalloproteinases by fibroblasts derived from normal and fibrotic human lung. Chest, 102: 1085-1089.
44. Yaguchi T, Fukuda Y, Ishizaki M et al. (1998). Immunohistochemical and gelatin zymography studies for matrix metalloproteinases in bleomycin-induced pulmonary fibrosis. Pathology International, 48: 954-963.
45. Madtes DK, Elston AL, Kaback LA et al. (2001). Selective induction of tissue inhibitor of metalloproteinase-1 in bleomycin-induced pulmonary fibrosis. American Journal of Respiratory Cell and Molecular Biology, 24: 599-607.
46. Lemjabbar H, Gosset P, Lechapt-Zalcman E et al. (1999). Overexpression of alveolar macrophage gelatinase B (MMP-9) in patients with idiopathic pulmonary fibrosis: effects of steroid and immunosuppressive treatment. American Journal of Respiratory Cell and Molecular Biology, 20: 903-913.
47. Betsuyaku T, Fukuda Y, Parks WC et al. (2000). Gelatinase B is required for alveolar bronchiolization after intratracheal bleomycin. American Journal of Pathology, 157: 525-535.
48. Corbel M, Caulet-Maugendre S, Germain N et al. (2001). Inhibition of bleomycin-induced pulmonary fibrosis in mice by the matrix metalloproteinase inhibitor batimastat. Journal of Pathology, 193: 538-545.
49. Winkler MK & Fowlkes JL (2002). Metalloproteinase and growth factor interactions: do they play a role in pulmonary fibrosis? American Journal of Physiology, 283: L-1-L-11.
50. Strieter RM (2002) Con: Inflammatory mechanisms are not a minor component of the pathogenesis of idiopathic pulmonary fibrosis. American Journal of Respiratory and Critical Care Medicine, 165: 1206-1207 (Discussion 1207-1208).
51. Corbel M, Théret N, Caulet-Maugendre S et al. (2001). Metalloproteinase activity is associated with inflammation and fibrosis following chronic lung injury in mice. Inflammation Research, 50: 129-135.
52. Serrano-Mollar A, Closa D, Prats N et al. (2003). In vivo antioxidant treatment protects against bleomycin-induced lung damage in rats. British Journal of Pharmacology, 138: 1037-1048.
53. Wang HD, Yamaya M, Okinaga S et al. (2002). Bilirubin ameliorates bleomycin-induced pulmonary fibrosis in rats. American Journal of Respiratory and Critical Care Medicine, 165: 406-411.
54. Punithavathi D, Venkatesan N & Babu M (2000). Curcumin inhibition of bleomycin-induced pulmonary fibrosis in rats. British Journal of Pharmacology, 131: 169-172.
55. Fattman CL, Chang LY, Termin TA et al. (2003). Enhanced bleomycin-induced pulmonary damage in mice lacking extracellular superoxide dismulase. Free Radical Biology and Medicine, 35: 763-771.
56. Manoury B, Nénan S, Leclerc O et al. (2005). The absence of reactive oxygen species production protects mice against bleomycin-induced pulmonary fibrosis. Respiratory Research, 6: 11.
57. Carver JE, Galloway WA & Robinson C (1999). Inhibition of gelatinase activity in human airway epithelial cells and fibroblasts by dexamethasone and beclomethasone. British Journal of Pharmacology, 127: 1119-1128.
58. Corbel M, Lagente V, Théret N et al. (1999). Comparative effects of betamethasone, cyclosporin and nedocromil sodium in acute pulmonary inflammation and metalloproteinase activities in bronchoalveolar lavage fluid from mice exposed to lipopolysaccharide. Pulmonary Pharmacology and Therapeutics, 12: 165-171.
59. Martin-Chouly CAE, Astier A, Jacob C et al. (2004). The selective phosphodiesterase 4 inhibitor CI-1044 inhibits TNF-α induced release of gelatinase A from human lung fibroblasts. Life Sciences, 75: 823-840.